Tom Wickham, PhD, brings over 25 years of experience in championing diverse drug platforms including cellular, gene, immuno-biologic, and liposomal therapies from discovery through registration-directed clinical trials. Tom joined GentiBio as the Chief Scientific Officer from Rubius Therapeutics where he was Senior Vice President of R&D. At Rubius, Tom pioneered synthetic biology approaches using engineered red cells for autoimmunity, immuno-oncology, and rare disease applications and built a Discovery and Preclinical organization leading to multiple product programs and IND filings. Prior to Rubius, he worked in different biotech and pharma companies across multiple technology platforms. Tom received his PhD in biochemical engineering from Cornell University and pursued his postdoctoral training at the Scripps Research Institute in the Department of Immunology.